• Patient or patient's legally authorized representative (LAR) or proxy can understand the purpose and risks of ALZ-NET and provide signed informed consent and authorization to use protected health information according to privacy rules.
• Patient is at least 18 years old at the time of informed consent.
• Patient has a diagnosis of mild cognitive impairment (MCI) or dementia with clinical suspicion of Alzheimer's disease as contributing pathology and is either being evaluated for treatment, will start treatment, or has already started treatment with novel FDA-approved Alzheimer's therapies.
• If treatment is started at consent, patient meets label requirements and appropriate use recommendations for the FDA-approved therapy.
• Patient's treating clinician decided on clinical care or treatment before consent and independently of ALZ-NET.

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety